Every 8-K that First Tracks Biotherapeutics, Inc. (TRAXV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRAXV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAXV filings page.
First Tracks Biotherapeutics reported combined first quarter 2026 results and outlined progress across its immunology pipeline following separation from AnaptysBio. The company launched with $180 million in cash and cash equivalents on April 20, 2026 and expects a roughly two‑year cash runway to advance lead programs.
For the three months ended March 31, 2026, research and development expenses were $34.0 million, down from $41.5 million a year earlier, while general and administrative expenses rose to $18.9 million from $9.8 million, mainly due to separation and stock‑based compensation costs. Net loss was $50.5 million compared with $47.2 million in the prior‑year period.
At March 31, 2026, First Tracks reported cash and cash equivalents of $248.5 million, short‑term investments of $38.0 million and total assets of $290.6 million. The update highlighted ongoing Phase 1b trials of ANB033 in celiac disease and eosinophilic esophagitis, an End‑of‑Phase 2 FDA meeting for rosnilimab in rheumatoid arthritis, and a near‑complete Phase 1a trial of ANB101 in healthy volunteers.
First Tracks Biotherapeutics, Inc. became an independent, publicly traded biotech company through a spin-off from AnaptysBio, with AnaptysBio shareholders receiving one First Tracks share for each AnaptysBio share held on the April 6, 2026 record date. The company simultaneously closed a private placement in which it issued 5,791,478 shares of common stock and EcoR1 Capital Fund Qualified, L.P. sold 4,705,575 of its spin-off shares to investors at $13.81 per share. A Separation and Distribution Agreement and a Transition Services Agreement allocate assets, liabilities, services and IP between AnaptysBio and First Tracks and govern post-spin relations. The company also adopted non-employee director cash and equity compensation programs and appointed Ajim Tamboli as Chief Financial Officer with a $516,000 base salary, target bonus opportunity and equity awards valued at $2,550,000. First Tracks’ lead programs include ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis and ANB101 in early-stage development, and its stock began trading on Nasdaq under the symbol TRAX.
First Tracks Biotherapeutics, Inc. outlines its planned separation from AnaptysBio through a taxable spin-off and concurrent private financing. AnaptysBio stockholders of record on April 6, 2026 will receive one First Tracks share for each AnaptysBio share when the distribution occurs on April 20, 2026.
First Tracks shares are expected to trade on Nasdaq under the symbol “TRAX”, with when-issued trading under “TRAXV” beginning April 6, 2026. A private placement will sell 5,791,478 new shares at $13.81 per share, targeting about $80 million in gross proceeds to fund the company’s clinical-stage immunology pipeline.